Q1 2026 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062419
$1.38B
Reported value
12
Positions
2026-03-31
Period end
The Brief · Fairmount Funds Management LLC · Q1 2026
AI · grounded in 13F
Fairmount Funds Management LLC established a new position in DMRA valued at $225.67M. The fund closed its positions in NUVALENT INC and KINIKSA PHARMACEUTICALS INTL, reducing exposure by $73.19M and $54.44M respectively. Additionally, the manager trimmed its holdings in APGE by 85.42% and COGT by 38.87%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 36322Q206 | DMRA | DAMORA THERAPEUTICS INC | $225.7M | 16.3% | 8,713,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $212.9M | 15.4% | 2,537,191 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $211.8M | 15.3% | 5,503,418 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $202.7M | 14.6% | 4,018,101 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $181.7M | 13.1% | 3,705,262 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $76.6M | 5.53% | 3,914,458 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $72.7M | 5.25% | 1,855,644 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $64.0M | 4.62% | 4,553,494 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $50.5M | 3.65% | 2,747,866 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $46.1M | 3.33% | 2,359,025 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $25.1M | 1.82% | 298,647 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $14.5M | 1.05% | 8,625,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.